可善挺cosentyx於2015年首先於日本核准用於乾癬性關節炎，隨後美國及台灣也已核准。用於乾癬性關節炎的使用方式與乾癬不同，美國是

For psoriatic arthritis patients with coexistent moderate to severe plaque psoriasis, use the dosage and administration for plaque psoriasis (2.1)
• For other psoriatic arthritis patients administer with or without a loading dosage. The recommended dosage:
o With a loading dosage is 150 mg at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter
o Without a loading dosage is 150 mg every 4 weeks
o If a patient continues to have active psoriatic arthritis, consider a dosage of 300 mg. (2.2)

台灣是

建議每次劑量為150 mg，起始於第0，1，2，3 和4 週皮下注射，接著於第4 週開始每4 週皮下注射。
但對於以腫瘤壞死因子阻斷劑(anti-TNFα) 治療反應不佳的病人，建議每次劑量為300 mg，起始於第0，1，2，3 和4 週皮下注射，接著於第4 週開始每4 週皮下注射。每次300 mg 劑量為給與兩次150 mg 皮下注射。
同時患有中度至重度斑塊性乾癬的病人，請參照斑塊性乾癬之建議劑量。

歐盟是

For patients with concomitant moderate to severe plaque psoriasis or who are anti-TNFα inadequate responders (IR), the recommended dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg.
For other patients, the recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4.

日本是

１回300mgを、初回、１週後、２週後、３週後、４週後に皮下投与し、以降、４週間の間隔で皮下投与する。また、体重により、１回150mgを投与することができる。〈用法及び用量に関連する使用上の注意〉⑴ 体重60kg以下の患者では 1 回150mgの投与を考慮すること。